Selective FGFR Inhibitor Shows Promise in Gastric and Breast Cancers


Gastric cancers with high-level clonal FGFR2 gene amplification responded to AZD4547, a selective FGFR inhibitor, in a phase II open label trial of previously treated, advanced FGFR amplified cancer. Yet tumors with multiple FGFR1 genes, low level or subclonal amplification of FGFR2 did not respond similarly to the drug.

Jennifer Brown, MD

Nicholas Turner, MD, PhD

Gastric cancers with high-level clonalFGFR2gene amplification responded to AZD4547, a selective FGFR inhibitor, in a phase II open label trial of previously treated, advancedFGFRamplified cancer. Yet tumors with multipleFGFR1genes, low level or subclonal amplification ofFGFR2did not respond similarly to the drug.

High-levelFGFR2amplification was found, during the course of the study, to initiate an oncogene addiction phenotype whereby the tumors become addicted to FGFR signaling. The reason for the addiction was investigated to better predict which patients may respond to targeted therapies inFGFRamplified cancers in the future.

“Our data provide a mechanistic understanding of the distinct pattern of oncogene addiction seen in highly-amplified cancers and demonstrate the importance of clonality in predicting response to targeted therapy,” wrote study authors.

In the study, advanced gastroesophageal cancer patients were screened forFGFR2gene amplification, which is present in about 8% of gastroesophageal cancers. NineFGFR2-positive patients were found, and of these, 3 patients (33%) had a confirmed partial response (PR) to AZD4547. The median progression-free survival (PFS) for responding patients was 6.6 months.

Responses were associated with higher copy numberFGFR2amplification in homogeneously amplified tumors. Two of the responding patients had clonal homogeneously amplified tumors. Each of the nonresponding patients had tumors with subclonal heterogeneous amplification with the presence of non-amplified tumor cells, including one patient who had a high-level amplified tumor with heterogeneous amplification that did not produce a response to AZD4547.

Patients withFGFR1amplification in estrogen receptor (ER)—positive breast cancer were also tested in the study. High-level amplification was more prevalent inFGFR2amplified cancers. Only 1 of 8FGFR1-positive breast cancer patients (12.5%) had a PR, and tumor reduction registered in theFGFR2amplified cancers alone.

High-levelFGFR2amplified cancers showed high sensitivity to FGFR inhibitors due to reliance on the PI3 kinase signaling. AmplifiedFGFR2activates PI3 kinase indirectly through transactivation of RAS and the concurrent binding of p85 to the receptor tyrosine kinases (RTKs) ERBB3 and IGF1R/IRS1, leading to PI3 kinase signaling becoming reliant upon FGFR signaling.

The study authors noted that thePIK3CAmutation does not occur inFGFR2amplified gastric cancers. This was proven by analysis of the Cancer Genome Atlas (TCGA) data, which showed the dependence of PI3 kinase pathway activation onFGFR2amplification.

Alternatively, other FGFR driven cell lines did not show the same reliance on the PI3K pathway. In low-levelFGFR1amplified cell lines PI3 kinase and mTOR signaling was not blocked by FGFR inhibition, as with high-levelFGFR2amplification. Signaling in theseFGFR1tumors was limited to MAPK signaling.

By exploiting the tumor addiction to FGFR signaling, therapies can be created to target theFGFR2cancer gene. Patients with this gene must first be identified.

The study authors wrote that high-level clonalFGFR2amplification may be detected in patients through circulating tumor DNA (ctDNA) screening, which would simplify the identification of patients that show sensitivity to FGFR inhibitors and would benefit from these kinds of treatments.

"We were able to design a blood test to screen for patients who were most likely to benefit from an FGFR2 inhibitor, helping us to target drug therapy at those patients who were most likely to benefit,” said study co-leader Nicholas Turner, MD, PhD, of the Institute of Cancer Research in London, in statement.

Emma Smith, PhD, science information manager for Cancer Research UK, which supported the study, wrote in a statement, “Developing ways to identify people who are most likely to benefit from drugs targeting particular genetic faults is vital to help ensure each patient gets the most effective treatment. The next steps will be larger clinical trials to see if testing for this genetic abnormality can spot people whose stomach cancer will respond well to this treatment.”

Reference: Pearson A, Smyth E, Babina IS, et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. [Published online May 13, 2016.] Cancer Discov. doi: 10.1158/2159-8290.CD-15-1246.

Related Videos
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"
Rebecca A. Shatsky, MD, an expert on breast cancer
Rebecca A. Shatsky, MD, an expert on breast cancer
Video 3 - "Managing Toxicities and Adverse Reactions in HR+/Her2-Low mBC Therapies"
Video 2 - "EMERALD: Underscoring Key Elacestrant Data + Subgroup Analyses for Informed Therapy Selection"
Video 1 - "A 62-Year-Old Woman with HR+ HER2-low Metastatic Breast Cancer and Lung, Liver, and Bone Metastases and Using Biomarker Testing to Guide Treatment Selection"
Related Content